AKAM vs TGTX · P/E 27, rev $2.17B vs P/E 18, rev $240.3M
Akamai Technologies Inc (AKAM) versus TG Therapeutics Inc (TGTX) — a side-by-side from cached financials, not a winner call.
Akamai Technologies Inc (AKAM) is a software - infrastructure company listed on US.
TG Therapeutics Inc (TGTX) is a biotechnology company listed on NASDAQ.
Latest reported AKAM revenue for 2026-06-30 was $2.17B. Net income was $185.7M. AKAM currently screens at market cap $11.31B and trailing P/E 26.7.
Latest reported TGTX revenue for 2026-06-30 was $240.3M. Net income was $7.8M. Revenue was up 17.3% from 2026-03-31 to 2026-06-30. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
AKAM currently screens at market cap $11.31B and trailing P/E 26.7. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
Not investment advice. Open the AKAM and TGTX stock pages for the full models.
Not investment advice.